Vietnam Tightens GMP Proof for China Herbal Extracts

On July 8, 2026, Vietnam’s Ministry of Agriculture and Rural Development (MARD) issued a new notice that changes the import documentation standard for herbal extract products originating from China. From August 15, 2026, the GMP certificate for these products must be issued by a provincial-level drug regulatory authority in China rather than a third-party certification body, and the document must also carry notarized Chinese-Vietnamese bilingual materials. For exporters, importers, processors, sourcing teams, and supply chain service providers involved in China-Vietnam herbal extract trade, this is worth close attention because it directly affects document validity, shipment readiness, and compliance timing in a trade flow said to cover about 73% of bilateral plant extract trade.

What the new notice formally changes

According to the information provided, MARD released Notice No. 89/2026/TT-BNNPTNT on July 8, 2026. The notice will take effect on August 15, 2026.

Its core requirement is that all herbal extract products originating from China must use a GMP certificate issued by a provincial-level drug supervision authority in China. GMP documents issued by third-party certification bodies are not accepted under this requirement.

The information also states that a notarized bilingual Chinese-Vietnamese version must accompany the relevant certificate materials. In addition, GMP proof previously issued by ISO certification bodies will no longer be accepted after the new rule takes effect.

Based on the information provided, the change is expected to affect about 73% of China-Vietnam plant extract trade flows.

Where the pressure is likely to appear across the trade chain

Export documentation moves to the center of compliance

From an industry perspective, direct trading companies handling herbal extract exports from China may be affected first because the rule changes the acceptable issuer of the GMP certificate itself. The immediate issue is not product description or pricing, but whether existing compliance files match Vietnam’s new entry standard. What deserves closer attention is whether current export portfolios still rely on third-party or ISO-related GMP proof that may become unusable after August 15, 2026.

Import and procurement teams face a document-screening risk

For importers and procurement-side businesses in Vietnam, the likely impact is concentrated in supplier qualification review, customs preparation, and order scheduling. Analysis shows that even where product demand remains unchanged, the acceptance threshold for supporting documents has shifted. That means buyers need to pay closer attention to the origin and format of GMP certificates, as well as whether notarized Chinese-Vietnamese bilingual materials are in place before shipment arrangements move forward.

Processors and manufacturers may see timing disruptions

For processing and manufacturing companies that depend on imported herbal extract inputs, the operational concern is less about the policy text itself and more about delivery continuity. Observably, if upstream suppliers cannot replace previously accepted third-party GMP documents in time, the effect may surface in order confirmation, inbound scheduling, and production planning. The key issue is whether compliance preparation can be completed within the short implementation window between July 8 and August 15, 2026.

Service providers will need tighter coordination on paperwork

Supply chain service providers, including those involved in document handling, certification support, and shipment coordination, may also see a more active role. The reason is straightforward: the new requirement combines issuer qualification with bilingual notarization, which increases the importance of document sequencing, review accuracy, and timeline control. For this group, the change is likely to be felt in pre-shipment checks and exception handling rather than in commercial negotiation.

What companies should watch before the rule takes effect

Check whether current GMP files remain valid under the new issuer rule

Analysis shows that the first practical step is to distinguish between GMP certificates issued by provincial-level drug supervision authorities in China and those issued by third-party or ISO-related certification bodies. The policy signal is narrow but specific: issuer identity now matters directly. Companies should therefore review existing supplier files and shipment documents against that point.

Do not treat notarized bilingual paperwork as a secondary detail

What deserves closer attention is that the notice is not limited to who issues the GMP certificate. It also requires Chinese-Vietnamese bilingual notarization. In practical terms, this can affect document preparation sequence, review lead time, and submission readiness. Businesses involved in near-term shipments should pay attention to whether translation and notarization steps are already built into their delivery schedule.

Separate confirmed rule text from implementation assumptions

Observably, the confirmed facts are the issuing authority requirement, the bilingual notarization requirement, the effective date, and the non-acceptance of ISO-issued GMP proof. Beyond that, companies should be careful not to treat internal interpretations or market rumors as settled enforcement detail. The immediate task is to align documentation with the confirmed text while continuing to monitor whether any additional official clarification appears.

Prepare supplier and customer communication around the transition window

From an industry perspective, the period before August 15, 2026 is likely to be sensitive for orders already in progress or documents already prepared under the previous practice. Companies should pay close attention to which shipments may be exposed to certificate replacement, re-notarization, or compliance rechecking, and communicate early with suppliers, buyers, and service partners where document ownership or submission timing could affect fulfillment.

Why this looks more than a routine paperwork update

Analysis shows that this development should not be read only as an administrative wording change. The adjustment moves GMP proof away from third-party certification acceptance and toward a regulator-issued standard for Chinese-origin herbal extract products entering Vietnam. That makes it more appropriate to understand this as a compliance tightening signal, even though the full business effect will depend on how companies adapt before the effective date.

At the same time, it is still more appropriate to treat the situation as an active compliance development rather than a fully settled long-term market conclusion. The rule text provided is clear on document requirements, but the broader operational consequences across suppliers, buyers, and logistics arrangements still need continued observation as the implementation date approaches.

How the market may need to read this change for now

In current terms, the notice matters because it changes the acceptability of core import documentation for Chinese herbal extract products in Vietnam within a short timeframe. The significance lies less in broad market rhetoric and more in the immediate compliance threshold for trade execution.

A neutral reading is that this is a concrete short-term regulatory change with potential wider implications if similar documentation standards begin to matter more across related transactions. For now, it is more appropriate to understand the update as both an immediate operational issue and a regulatory signal that still warrants close follow-up.

Basis of this article and what still needs verification

This article is generated based on the user-provided news title, event date, and event summary. The confirmed content used here is limited to the stated MARD notice number, the July 8, 2026 release date, the August 15, 2026 effective date, the requirement that GMP certificates for China-origin herbal extract imports be issued by provincial-level drug supervision authorities in China, the Chinese-Vietnamese bilingual notarization requirement, the non-acceptance of ISO-issued GMP proof, and the stated impact on about 73% of China-Vietnam plant extract trade flow.

For this type of industry update, common source categories usually include official government notices, company disclosures, industry association releases, authoritative media reporting, and standard-setting documents. A specific official source link was not provided in the input, so the exact publication record should continue to be verified. What remains worth tracking is whether any further official clarification, implementation guidance, or related market communication emerges after the notice date and before the August 15, 2026 effective date.